首页膀胱肿瘤病因/危险因素证据详情

Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis

原文: 2021 年 发布于 Diagnostics (Basel) 10 卷 第 8 期 728-738 浏览量:240次

作者: Geng Z. Geng Q.

作者单位: Department of Urology, Jacksonville College of Medicine, University of Florida, Jacksonville, FL, 32209, USA. S.b.jazayeri@gmail.com. Department of Urology, Jacksonville College of Medicine, University of Florida, Jacksonville, FL, 32209, USA. Department of Urology, University of Florida College of Medicine, Gainesville, FL, USA.

归属分类: 膀胱肿瘤病因/危险因素证据

DOI: 10.1007/s00120-022-01765-z

关键词: Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

文献简介

Objective To assess the effect of fibrin clot inhibitors (aspirin, clopidogrel, and warfarin) and statins on intravesical BCG therapy. Method A systematic literature search was carried out through PubMed, Embase, and the Cochrane Central Search Library in March 2020. Accumulative analyses of odds ratios (ORs), hazard ratio (HR), and corresponding 95% confidence intervals (CIs) were performed. All analyses were performed by using Review Manager software version 5.3 and Stata 15.1. Results Four cohort studies and nine case-control studies containing 3,451 patients were included. The pooled analysis indicated that statins (HR = 1.00; 95%CI, 0.82 to 1.22; p = 1.00) and fibrin clot inhibitors (HR = 1.01; 95%CI, 0.64 to 1.59; p = 0.98) did not affect the efficacy of BCG on recurrence-free survival. The cumulative analysis showed that statins (HR = 0.79; 95%CI, 0.41 to 1.49; p = 0.46) and fibrin clot inhibitors (HR = 1.62; 95%CI, 0.90 to 2.91; p = 0.11) did not affect the efficacy of BCG on progression-free survival. There were no differences on cancer-specific survival (HR = 1.68; 95%CI, 0.64 to 4.40; p = 0.29) and overall survival (HR = 1.13; 95%CI, 0.73 to 1.78; p = 0.58) after taking statins. Conclusion The present study shows that the application of fibrin clot inhibitors and statins do not influence the efficacy of BCG on oncological prognosis. Consequently, we do not need to stop using them or change to other drugs during intravesical BCG treatment. However, large-scale multi-center prospective research is still needed to confirm the above conclusions.

热门文献